CIT expands US presence

Appoints vice-president of business development North America

CIT, a French non-clinical CRO, has opened a US subsidiary, CITox, in Boston, Massachusetts, to spearhead the planned expansion of its US activities.

The company has appointed Bernard Galat as vice-president, business development, North America, who will be based in the Boston office.

The US represents 15% of CIT’s current sales; the aim is to increase this to 30% in three to five years.

Prior to joining CIT, Galat held senior sales and marketing positions with Xceleron, Parexel and Carestat.

‘This is an exciting time to be joining CIT as we expand the availability of our services in monoclonal antibody therapies, tissue cross-reactivity, functional genomics, safety pharmacology and carcinogenicity, including transgenic models,’ he said.

You may also like

Research & Development

CiToxLAB expands inhalation test capabilities in North America and Europe

Opens rodent and non-rodent facility in Canada and will double rodent capacity in Hungary
Regulatory

CiToxLAB emerges from CIT and LAB Research merger

Will provide pre-clinical and specialist services from four facilities
Regulatory

CIT acquires assets of LAB Research Inc

This acquisition makes the new group one of the world’s top preclinical CROs
Research & Development

CIT to purchase LAB Research

Acquisition will take Canadian CRO out of receivership
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Finance

Evestia Clinical to merge with Atlantic Research Group

The merger delivers on Evestia Clinical’s strategy of targeted growth through the expansion of services, enhanced technology and broadened geographical reach
Subscribe now